Non Hodgkin Lymphoma Clinical Trial

PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study

Summary

The purpose of this study is to see how a new drug, named PUH71, accumulates in the different parts of the body & inside tumors and how long PUH71 lasts in the blood, when given to study participants in tiny amounts. The results of this study will help researchers (1) plan how they will use PUH71 as an experimental new drug (at much-higher doses) for the treatment of cancer, in clinical trials; and (2) know whether PUH71 might be used as a drug for detecting tumors with scanner machines.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients with solid malignancy, myeloproliferative neoplasm, myeloma, and/or lymphoma (histology confirmed by MSKCC Department of Pathology)
Disease is measurable or evaluable as defined by RECIST (1.1 or original version) or other tumor response criteria from an MSKCC IRB-approved clinical research protocol.
This does not apply to patients with myeloproliferative neoplasm. The presence of active myeloproliferative neoplasm will be determined by applicable disease specific diagnostic criteria and patient assessment by the patient's oncologist and trial investigators (eg, manifestations of active MPN such as splenomegaly, abnormal blood counts, etc).
Age between 18-90
Negative serum pregnancy test for females of childbearing age (11-55 years) and/or lack child-bearing potential
No breast-feeding

Exclusion Criteria:

Previous allergic reaction to contrast medium.
Hypersensitivity to iodide products.
Known hyperthyroidism

Hepatic:

Bilirubin > 1.5 x institutional upper limit of normal (ULN)
AST/ALT >2.5 x ULN
Albumin < 2 g/dl
GGT > 2.5 x ULN IF Alkaline phosphatase > 2.5 x ULN. Renal: Creatinine >1.5 x ULN or creatinine clearance < 60 mL/min.
Positive serum pregnancy test for females
Acute major illness (e.g., infection, unstable cardiovascular condition, etc.)

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Early Phase 1

Estimated Enrollment:

63

Study ID:

NCT01269593

Recruitment Status:

Active, not recruiting

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Early Phase 1

Estimated Enrollment:

63

Study ID:

NCT01269593

Recruitment Status:

Active, not recruiting

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.